Login to Your Account



Antibiotic Firm Paratek Joins IPO Queue; Aiming for $92M

By Jennifer Boggs
Managing Editor

Monday, October 1, 2012
The latest biotech hoping to take advantage of the new emerging growth company category under the Jumpstart Our Business Startups (JOBS) Act of 2012, antibiotic developer Paratek Pharmaceuticals Inc. filed for an initial public offering (IPO) aiming to raise $92 million as it takes thrice partner-dumped omadacycline into Phase III testing on its own.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription